The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...

Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

A study suggests that weight loss medications like Ozempic may help reduce the risk of overdose and alcohol intoxication in ...

The Beijing IP Court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...